WINTON GROUP Ltd Has $2 Million Holdings in LifeStance Health Group, Inc. $LFST

WINTON GROUP Ltd raised its position in shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 522.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 186,589 shares of the company's stock after buying an additional 156,607 shares during the quarter. WINTON GROUP Ltd's holdings in LifeStance Health Group were worth $1,998,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. IFP Advisors Inc raised its holdings in shares of LifeStance Health Group by 316.5% during the second quarter. IFP Advisors Inc now owns 3,694 shares of the company's stock valued at $40,000 after acquiring an additional 2,807 shares during the period. Larson Financial Group LLC boosted its stake in LifeStance Health Group by 19,952.6% in the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company's stock worth $27,000 after purchasing an additional 3,791 shares during the period. KBC Group NV purchased a new position in LifeStance Health Group during the 1st quarter worth approximately $29,000. EverSource Wealth Advisors LLC raised its stake in LifeStance Health Group by 359.1% during the 1st quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company's stock valued at $44,000 after purchasing an additional 5,404 shares during the period. Finally, Integrated Wealth Concepts LLC acquired a new stake in LifeStance Health Group during the 2nd quarter valued at $91,000. 85.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on LFST shares. The Goldman Sachs Group started coverage on LifeStance Health Group in a report on Friday, June 5th. They issued a "neutral" rating and a $9.00 target price for the company. Zacks Research downgraded LifeStance Health Group from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 13th. Canaccord Genuity Group raised their price objective on LifeStance Health Group from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Wednesday. JPMorgan Chase & Co. boosted their price objective on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, August 14th. Finally, KeyCorp upped their price objective on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company an "overweight" rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $12.88.

Insider Transactions at LifeStance Health Group

In other LifeStance Health Group news, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of LifeStance Health Group stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.62, for a total value of $144,890,858.34. Following the completion of the sale, the insider directly owned 98,101,407 shares in the company, valued at $1,041,836,942.34. The trade was a 12.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Lisa K. Miller sold 47,912 shares of the business's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $519,845.20. Following the completion of the sale, the chief operating officer directly owned 281,289 shares of the company's stock, valued at $3,051,985.65. This represents a 14.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 14,671,917 shares of company stock worth $155,493,415. Corporate insiders own 3.50% of the company's stock.

Trending Headlines about LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Barclays raised its price target for LifeStance Health Group from $13 to $15 and maintained an “overweight” rating, implying further upside from the stock’s recent level. Barclays price target report
• Positive Sentiment: Zacks highlighted LFST as a strong momentum candidate, reinforcing investor interest after the shares’ substantial appreciation over the past year. Zacks momentum stock analysis
• Positive Sentiment: The company’s latest quarterly results showed strong operating momentum: revenue increased 26.1% year over year to $435.4 million, while adjusted earnings of $0.06 per share exceeded expectations of $0.03. The company is also projected to remain profitable for the full year.
• Neutral Sentiment: LifeStance announced a secondary offering alongside a share repurchase program. The repurchase could help absorb some of the shares being offered and support the stock, although the overall effect depends on the offering size and terms. LifeStance secondary offering and share repurchase announcement
• Neutral Sentiment: Brokerages collectively rate LFST a “Moderate Buy,” suggesting generally favorable expectations but not unanimous conviction.
• Negative Sentiment: The secondary offering may create additional share supply and weigh on the stock in the near term, particularly after its sharp run-up. The stock also trades at a high valuation—roughly 100 times earnings—leaving it sensitive to changes in growth expectations.

LifeStance Health Group Price Performance

LFST opened at $12.97 on Friday. The stock has a fifty day moving average price of $11.67 and a 200 day moving average price of $9.00. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.18. LifeStance Health Group, Inc. has a 1 year low of $4.77 and a 1 year high of $13.28. The stock has a market cap of $4.96 billion, a price-to-earnings ratio of 99.78 and a beta of 1.22.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. The company had revenue of $435.35 million for the quarter, compared to analyst estimates of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The business's revenue was up 26.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.01) EPS. Analysts forecast that LifeStance Health Group, Inc. will post 0.16 EPS for the current fiscal year.

LifeStance Health Group Profile

LifeStance Health Group, Inc is a behavioral health care company that provides outpatient mental health services through in-person and virtual appointments. Its platform connects patients with psychiatrists, psychologists, psychiatric nurse practitioners, therapists and other licensed clinicians.

The company offers services that may include psychotherapy, psychiatric evaluations, medication management and treatment for conditions such as anxiety, depression, attention-deficit/hyperactivity disorder and other behavioral health needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.